3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
11
Neoplasm Metastasis
2
HER2 Positive Metastatic Breast Cancer
2
Urinary Bladder Neoplasms
1
Oesophagogastric Cancer
1
Neoplasms
1
Invasive Breast Cancer
1
HER2-positive Advanced Breast Cancer
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Diseases
1
Interventions
Carboplatin
84
Cisplatin
79
Pemetrexed
72
Docetaxel
62
Drug Therapy
44
Gemcitabine
43
Erlotinib Hydrochloride
42
Gefitinib
38
Radiotherapy
36
Paclitaxel
36
pembrolizumab
31
Bevacizumab
29
icotinib
28
osimertinib
27
anlotinib
26
Nivolumab
26
camrelizumab
23
Vinorelbine
23
Radiosurgery
20
aumolertinib
18
atezolizumab
17
sintilimab
16
apatinib
16
Endostatins
16
endostar protein
15
durvalumab
14
Surgical Procedures, Operative
13
Immunotherapy
13
Immune Checkpoint Inhibitors
12
Blood Specimen Collection
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Carcinoma, Non-Small-Cell Lung
×
Lapatinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled